[
    [
        {
            "time": "2021-03-30",
            "original_text": "复星医药去年扣非净利润27亿增长22%，上市新药贡献收入超10亿",
            "features": {
                "keywords": [
                    "复星医药",
                    "扣非净利润",
                    "增长",
                    "上市新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药去年扣非净利润27亿增长22%，上市新药贡献收入超10亿",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星医药董事长吴以芳：生物类似药大大提升药物可及性，不排除部分品种被纳入集采",
            "features": {
                "keywords": [
                    "复星医药",
                    "吴以芳",
                    "生物类似药",
                    "集采"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药董事长吴以芳：生物类似药大大提升药物可及性，不排除部分品种被纳入集采",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星医药(600196)：符合预期 BD和自主研发能力进入加速兑现期",
            "features": {
                "keywords": [
                    "复星医药",
                    "BD",
                    "自主研发",
                    "加速兑现"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(600196)：符合预期 BD和自主研发能力进入加速兑现期",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "郭广昌2021致股东信：最挑战的一年 最好的一年",
            "features": {
                "keywords": [
                    "郭广昌",
                    "股东信",
                    "挑战",
                    "最好"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "郭广昌2021致股东信：最挑战的一年 最好的一年",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复宏汉霖：2020年成绩亮眼 创新加速 盈利在望",
            "features": {
                "keywords": [
                    "复宏汉霖",
                    "创新",
                    "盈利"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复宏汉霖：2020年成绩亮眼 创新加速 盈利在望",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星国际(00656)公布2020年业绩：总收入1366亿元，收购DJULA、舍得酒、金徽酒等领先品牌",
            "features": {
                "keywords": [
                    "复星国际",
                    "总收入",
                    "收购",
                    "品牌"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星国际(00656)公布2020年业绩：总收入1366亿元，收购DJULA、舍得酒、金徽酒等领先品牌",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星国际(00656)2020年末期息每股22港仙 归母净利约80.18亿元",
            "features": {
                "keywords": [
                    "复星国际",
                    "末期息",
                    "归母净利"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星国际(00656)2020年末期息每股22港仙 归母净利约80.18亿元",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复兴医药引进的CXCR4拮抗剂临床申请获受理",
            "features": {
                "keywords": [
                    "复兴医药",
                    "CXCR4拮抗剂",
                    "临床申请",
                    "受理"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复兴医药引进的CXCR4拮抗剂临床申请获受理",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星医药吴以芳：不排除生物类似药会进集采 要做好产能准备",
            "features": {
                "keywords": [
                    "复星医药",
                    "吴以芳",
                    "生物类似药",
                    "集采",
                    "产能"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药吴以芳：不排除生物类似药会进集采 要做好产能准备",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星医药CEO：复星医药提交BioNTech在中国的疫苗数据",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "疫苗",
                    "数据"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药CEO：复星医药提交BioNTech在中国的疫苗数据",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星医药去年扣非净利润27亿增长22% 新冠疫苗利润未兑现已被叫停",
            "features": {
                "keywords": [
                    "复星医药",
                    "扣非净利润",
                    "新冠疫苗",
                    "利润",
                    "叫停"
                ],
                "sentiment_score": 0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药去年扣非净利润27亿增长22% 新冠疫苗利润未兑现已被叫停",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星医药2020年实现扣非净利润27.18亿元 同比增长21.65%",
            "features": {
                "keywords": [
                    "复星医药",
                    "扣非净利润",
                    "增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药2020年实现扣非净利润27.18亿元 同比增长21.65%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "港股公告精选：比亚迪股份预计首季净利同比上升77.56%至166.34%",
            "features": {
                "keywords": [
                    "比亚迪",
                    "首季净利",
                    "同比上升"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "汽车"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股公告精选：比亚迪股份预计首季净利同比上升77.56%至166.34%",
                "Correlation": 1,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星医药去年净利增10.27% 全年研发投入逾40亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利增",
                    "研发投入"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药去年净利增10.27% 全年研发投入逾40亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-03-30",
            "original_text": "复星医药(02196.HK)2020年纯利升10.27%至36.63亿元 过亿单品达39个",
            "features": {
                "keywords": [
                    "复星医药",
                    "纯利",
                    "过亿单品"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)2020年纯利升10.27%至36.63亿元 过亿单品达39个",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]